Introduction
============

Major depressive disorder (MDD) is a common and recurrent mental illness with a lifetime prevalence of 5%--12% in adult men and 9%--26% in adult women. In spite of recent advances in psychopharmacology, approximately 60% of patients with MDD do not achieve an adequate response or remission to initial antidepressant therapy (ADT) even with adequate dose and duration.[@b1-ndt-11-225]

Common strategies adopted for nonresponders to ADT include switching to other antidepressants, combining therapy with antidepressants of another class, and augmentation strategies with atypical antipsychotics, lithium, or thyroid hormone.[@b2-ndt-11-225]--[@b4-ndt-11-225] The United States Food and Drug Administration (FDA) has approved aripiprazole and quetiapine as adjunctive treatment for MDD,[@b5-ndt-11-225] however few studies have been conducted on the actual choices of psychiatrists for nonresponders to ADT.

The prescribing behavior of physicians is influenced by many factors, including evidence-based medical knowledge, training and continuous education, and largely by health insurance and reimbursement or payment policies.[@b6-ndt-11-225]--[@b8-ndt-11-225] The aim of this study was to examine how Taiwanese psychiatrists prescribe medication and how they are influenced by health insurance payments and admini strative policy.

Methods
=======

This descriptive study used an innovative questionnaire for Taiwanese psychiatrists on augmentation strategy for MDD patients with an inadequate response to ADT. The aim of this questionnaire was to examine the influence of health insurance payments and administrative policy on the prescribing behavior of Taiwanese psychiatrists. The first question asked how many MDD outpatients per month each Taiwanese psychiatrists treated. The second question asked about the percentage of poor responders to ADT, and the third question asked about the remission rate of MDD. The fourth question asked about the strategies used for the poor responders to ADT, and the fifth question asked which antipsychotics were chosen for antipsychotic augmentation therapy. The sixth and seventh questions asked why and why not aripiprazole was chosen as the augmentation antipsychotic. The eighth question asked why augmentation antipsychotics were not chosen. We handed out the questionnaire during the annual meeting of the Taiwanese Society of Psychiatry in October 2012.

Statistical analysis
====================

Outpatient visits per month, percentage of poor responders to ADT, remission rate, the strategies used for the poor responders to ADT, and choice of augmentation antipsy-chotics were presented with numbers and percentages. The answers to questions 4--8 according to the number of MDD outpatients per month were compared using chi-square and Fisher's exact tests. Analysis of covariance (ANCOVA) was used to analyze the relationship between the answers to questions 4--8 and the number of MDD outpatients per month after including poor response proportion and remission rate as covariates. Multiple logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the correlate variables associated with aripiprazole and quetiapine. The IBM SPSS Statistics version 22 (IBM^®^ SPSS^®^ Statistics 22, IBM, New York, NY, USA) was used for statistical analysis, and the significance level (*P*-value) was set at 0.05.

Results
=======

We collected 324 questionnaires with complete data. The most common strategies for treating MDD patients with an inadequate response to ADT were switching to antidepressants with different mechanisms (76.4%), augmentation with antipsychotics (76.1%), combination with other antidepressants (35.4%), and electroconvulsive therapy (14.6%) ([Table 1](#t1-ndt-11-225){ref-type="table"}).

The antipsychotics used for MDD were aripiprazole (78.2%), quetiapine (62%), olanzapine (34.6%), risperidone (30.2%), and sulpiride (27.4%). The reasons psychiatrists chose aripiprazole for augmentation included fewer adverse effects (72.5%), good response (59.7%), FDA indication (55.6%), and rapid onset of action (33.4%). The psychiatrists who chose not to prescribe aripiprazole as the augmentation antipsychotic did so because of price (52.1%), official insurance policy audit and deletion of payments (30.8%), adverse effects (29.2%), response (12.7%), and not knowing enough about the drug (8.3%). Concerns when considering augmentation antipsychotics were insurance audit and deletion (53%), price (36.6%), side effects (35%), response (12%), and not knowing enough about the drug (1.9%) ([Table 1](#t1-ndt-11-225){ref-type="table"}).

The data in [Table 2](#t2-ndt-11-225){ref-type="table"} reveals several statistical differences among groups of those who treated different numbers of MDD patients per month (\<100, 101--200, and \>200), in the antipsychotics chosen, the reasons why they did not choose aripiprazole, and the reasons why they did not choose antipsychotics for augmentation. For example, the reason why psychiatrists in the group of 101--200 treated patients/month, chose not to augment with antipsychotics due to "health insurance payment audit and deletion", is significantly higher than other groups (76 in 129, 59.4%, *P*\<0.001 in ANCOVA) ([Table 2](#t2-ndt-11-225){ref-type="table"}).

In further analysis by the number of patients the psychiatrists treated per month, those who saw 101--200 persons/month were more likely to choose quetiapine and olanzapine as augmentation strategy, but those who saw more than 200 persons/month were less likely to choose quetiapine and olanzapine as augmentation strategy. There was no difference in choosing aripiprazole as the augmentation strategy between the groups ([Table 3](#t3-ndt-11-225){ref-type="table"}).

Discussion
==========

Treatment-resistant depression is associated with extensive use of general and psychiatric medical services, which poses substantial economic burden and work loss costs.[@b9-ndt-11-225],[@b10-ndt-11-225] The prescribing behavior of psychiatrists may influence the outcomes of refractory MDD and cause a delay in the use of adequate antipsychotic augmentation therapy. It is important therefore for health policy makers to understand the prescribing behav-iors and modify the insurance policy accordingly.

The national health care system in Taiwan, known as the National Health Insurance (NHI) program, was instituted in 1995. The NHI program is a single-payer compulsory social insurance plan which centralizes the disbursement of health care funds.[@b11-ndt-11-225],[@b12-ndt-11-225] The system promises equal access to health care for all citizens, and the population coverage had reached 99% by the end of 2004.[@b13-ndt-11-225],[@b14-ndt-11-225] Although patient satisfaction with the NHI program was reported to be more than 80% in 2011,[@b15-ndt-11-225] doctors have reported dissatisfaction because of instability in NHI regulations, a complicated medical claims system, and excessive working hours.[@b16-ndt-11-225] Doctors can be heavily penalized for a wide variety of reasons such as seeing too many patients or offering too many services even if they were appropriate under a budget-reduction scenario and reduced-payment physician payment policy and claims review system.[@b17-ndt-11-225]

In Taiwan, the NHI payment policy adopts a unique way in the denial of prescriptions payment, which is called "insurance policy audit and deletion of payments". The auditors act by "post-hoc" denial, or deletion, of payment for the medications. For example, while some health care providers (including psychiatrists) prescribe medications costlier than those prescribed daily by other peer health care providers, auditors could delete the payment for these medications. This doesn't just mean that the NHI denied the payment per se, but also means a 100-fold penalty, that is, 100-fold of the price of the denied medications must be paid back to the NHI by the health care providers.[@b18-ndt-11-225]--[@b20-ndt-11-225] The sampling rate of cases for auditing is one-fifteenth (6.67%) of the medical cases submitted monthly by individual health care providers.[@b21-ndt-11-225]

MDD is one of the major mental illnesses treated by Taiwanese psychiatrists, many of whom agree that an inadequate poor response to ADT is common. Although 50%--60% of patients respond to first-line treatment, only 35%--40% of patients were reported to experience a remission of symptoms during an initial 8-week trial.[@b1-ndt-11-225] In Taiwan, the inadequate response rate has been reported to be 30%. Most psychiatrists in Taiwan agree that around 60% of MDD patients can achieve remission, which is close to that reported with venlafaxine (59.3%), and higher than that reported in previous studies with conventional antidepressants (ie, paroxetine, citalopram, sertraline, fluoxetine, mirtazapine, or other treatments),[@b22-ndt-11-225] which may imply that Taiwanese psychiatrists overestimate the MDD remission rate.

Other than medical knowledge and training, physician prescribing behavior is largely influenced by pharmaceutical promotions,[@b23-ndt-11-225] health insurance payments, and administrative policy. As previously reported, health insurance policy can jeopardize patient benefits when physicians are required to conform to the finance-driven regulatory rules of health insurance companies.[@b7-ndt-11-225],[@b8-ndt-11-225],[@b24-ndt-11-225] Switching to venlafaxine, for example, has been shown to have a higher response rate after selective serotonin reuptake inhibitor (SSRI) failure.[@b22-ndt-11-225] However, in Taiwan, approximately the same number of psychiatrists choose switching as choose augmentation.

Three randomized controlled trials demonstrated that aripiprazole augmentation is useful for antidepressant non-responders, and that it should be reserved for nonresponders after 6 weeks of adequate ADT.[@b25-ndt-11-225],[@b26-ndt-11-225] There is currently no consensus on the duration of aripiprazole augmentation, however current American Psychiatric Association MDD guidelines recommend the same dose used for the acute phase as in the continuation and maintenance phases.[@b27-ndt-11-225] The most common adverse effect of aripiprazole is akathisia, which occurs in about 23.1% of the patients treated with aripiprazole,[@b25-ndt-11-225] and can be treated with propranolol. Many Taiwanese psychiatrists choose aripiprazole and quetiapine as augmentation antipsychotics, however up to 30% of Taiwanese psychiatrists still choose off-label olanzapine (34.6%), risperidone (30.2%), and sulpiride (27.4%). In Taiwan, psychiatrists are allowed to prescribe medications for off-label use,[@b28-ndt-11-225]--[@b31-ndt-11-225] but off-label use of prescriptions are one of the exclusion criteria for drug relief in the Taiwan Drug Hazard Relief Act, which was enacted in 2000.[@b32-ndt-11-225],[@b33-ndt-11-225]

The main reasons why psychiatrists do not choose aripiprazole are price, insurance audit and deletion, and adverse effects. Aripiprazole costs US\$0.33 per mg in Taiwan, and therefore a dose ranging from 2--10 mg/d costs US\$0.66--3.30 per day. Whereas, antidepressants cost US\$0.14--0.95 per tablet for SSRI, and US\$0.90--1.07 per tablet for (serotonin-norepinephrine reuptake inhibitor) SNRI. So an adequate dose of SSRI costs US\$0.14--0.95 per day and US\$2.70--3.20 per day for SNRI.[@b34-ndt-11-225]

The switching strategy is cheaper than augmentation strategy. In 2004, the average daily drug price for depressive outpatients in Taiwan was estimated to be US\$1.3±1.316.[@b35-ndt-11-225] Insurance payment is an important concern for Taiwan psychiatrists. If the prescription is audited and deleted in outpatients, the penalty is up to 100-fold the medication price.[@b20-ndt-11-225] We speculate that insurance audit and deletion is the main reason why Taiwanese psychiatrists do not choose aripiprazole as an augmentation strategy. In contrast to the American Psychiatric Association's willingness to sue insurers over American Medical Association's Current Procedural Terminology code violations,[@b36-ndt-11-225] the Taiwanese Society of Psychiatry has taken little action against insurance audit and deletion.

Few previous studies have discussed psychiatrists' decision-making. In one study concerning the prescription of benzodiazepines, the decision-making was found to be influenced by concerns of fear of supply, initiating substance abuse, or even diversions in patients, especially when facing time limits and patient manipulation, however insurance coverage issues were not mentioned.[@b37-ndt-11-225] Similar to a study which reported that the prescription of non-steroid anti-inflammatory drugs (NSAIDs) or NSAIDs with gas-troprotective therapy to the elderly with osteoarthritis was influenced by the reimbursement policy in Canada,[@b7-ndt-11-225] the prescribing behavior by Taiwanese psychiatrists for antipsy-chotic augmentation seems to be affected by health insurance payment policy.

The response to placebo in antidepressant drug trials for MDD is highly variable and has increased significantly in recent years.[@b38-ndt-11-225] Two main mechanisms underlie the effect of placebo administration: conditioned reflexes, which are subconscious, and the patient's expectations, which are conscious. Other factors in placebo administration relate to the doctor's influence on the patient's attitude to his or her disease. This can be referred to as the "context effect".[@b39-ndt-11-225] Placebo effects may explain why off-label use of atypical antipsychotics is common among Taiwanese psychiatrists.

The main limitation of this study is lack of demographic data, for most of the psychiatrists did not offer their detailed personal information. However, the total numbers of psychiatrists was nearly 1,436 in the year of the study, 2012,[@b40-ndt-11-225] therefore, nearly one in every five (22.56%) Taiwan psychiatrists responded to this questionnaire, which could be representative of this group.

Conclusion
==========

Antipsychotic augmentation with aripiprazole and quetiapine is recommended for MDD patients with a poor response to ADT, however many Taiwanese psychiatrists still choose a switching strategy. Price and insurance audit and deletion affected the intention to prescribe aripiprazole. We suggest that prescribing behavior by Taiwan psychiatrists for antipsy-chotic augmentation is affected by health insurance policy.
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###### 

Questionnaire for Taiwanese psychiatrists on MDD patients with a poor response to ADT

  Question                                                                                             Category                                                   Number (n=324)   Percent (%)
  ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ---------------- -------------
  1\. How many outpatients with major depressive disorder do you treat per month?                      Below 50 persons                                           62               19.1
  50--100 persons                                                                                      92                                                         28.4             
  101--150 persons                                                                                     69                                                         21.3             
  151--200 persons                                                                                     60                                                         18.5             
  More than 200 persons                                                                                41                                                         12.7             
  2\. What proportion of your MDD patients have a poor response to antidepressant therapy?             Below 10%                                                  7                2.2
  10%--20%                                                                                             76                                                         23.7             
  20%--30%                                                                                             158                                                        49.2             
  30%--40%                                                                                             60                                                         18.7             
  Above 40%                                                                                            20                                                         6.2              
  3\. What is the remission rate of MDD patients with antidepressant therapy?                          Below 50%                                                  52               16.3
  50%--60%                                                                                             128                                                        40.1             
  60%--70%                                                                                             69                                                         21.6             
  70%--80%                                                                                             61                                                         19.1             
  Above 80%                                                                                            9                                                          2.8              
  4\. How will you treat patients with a poor response to antidepressant therapy? (multiple choices)   Switch to other antidepressants with different mechanism   246              76.4
  Augmentation antipsychotics                                                                          245                                                        76.1             
  Combination with other antidepressants                                                               114                                                        35.4             
  ECT                                                                                                  47                                                         14.6             
  Others                                                                                               9                                                          2.8              
  5\. Which antipsychotics do you often prescribe? (multiple choices)                                  Aripiprazole                                               251              78.2
  Olanzapine                                                                                           111                                                        34.6             
  Quetiapine                                                                                           199                                                        62.0             
  Risperidone                                                                                          97                                                         30.2             
  Sulpiride                                                                                            88                                                         27.4             
  Others                                                                                               7                                                          2.2              
  6\. Why did you choose aripiprazole? (multiple choices)                                              Good effect                                                191              59.7
  Rapid onset                                                                                          107                                                        33.4             
  Few adverse effects                                                                                  232                                                        72.5             
  Cheap price                                                                                          13                                                         4.1              
  FDA indication                                                                                       178                                                        55.6             
  Others                                                                                               2                                                          0.6              
  7\. Why did you not choose aripiprazole? (multiple choices)                                          Effect                                                     40               12.7
  Adverse effects                                                                                      92                                                         29.2             
  Price                                                                                                164                                                        52.1             
  Not knowing enough about the drug                                                                    26                                                         8.3              
  Health insurance payment audit and deletion                                                          97                                                         30.8             
  Others                                                                                               12                                                         3.8              
  8\. Why did you not choose augmentation antipsychotics? (multiple choices)                           Effect                                                     38               12.0
  Adverse effects                                                                                      111                                                        35.0             
  Price                                                                                                116                                                        36.6             
  Not knowing enough about the drug                                                                    6                                                          1.9              
  Health insurance audit and deletion                                                                  168                                                        53.0             
  Others                                                                                               32                                                         10.1             

**Abbreviations:** ADT, antidepressant therapy; ECT, electroconvulsive therapy; MDD, major depressive disorder; FDA, US Food and Drug Administration.

###### 

Analysis of medication selection according to the number of MDD outpatients per month

  Question                                                                                             Category                                                    Number of MDD outpatients per month   *P*-value[a](#tfn2-ndt-11-225){ref-type="table-fn"},[b](#tfn3-ndt-11-225){ref-type="table-fn"}   *P*-value[c](#tfn4-ndt-11-225){ref-type="table-fn"}             
  ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------------- --------- -------
  4\. How will you treat patients with a poor response to antidepressant therapy? (multiple choices)   Switch to other antidepressants with different mechanisms   107 (69.9)                            109 (84.5)                                                                                       30 (75.0)                                             0.016     0.038
  Augmentation antipsychotics                                                                          111 (72.5)                                                  99 (76.7)                             35 (87.5)                                                                                        0.139                                                 0.255     
  Combination with other antidepressants                                                               47 (30.7)                                                   52 (40.3)                             15 (37.5)                                                                                        0.234                                                 0.208     
  ECT                                                                                                  25 (16.3)                                                   19 (14.7)                             3 (7.5)                                                                                          0.37                                                  0.079     
  Total (n=322)                                                                                        153 (100.0)                                                 129 (100.0)                           40 (100.0)                                                                                                                                                       
  5\. Which antipsychotics do you often prescribe? (multiple choices)                                  Aripiprazole                                                118 (77.6)                            99 (76.7)                                                                                        34 (85)                                               0.529     0.722
  Olanzapine                                                                                           53 (34.9)                                                   53 (41.1)                             5 (12.5)                                                                                         0.004                                                 0.004     
  Quetiapine                                                                                           85 (55.9)                                                   97 (75.2)                             17 (42.5)                                                                                        \<0.001                                               \<0.001   
  Risperidone                                                                                          59 (38.8)                                                   29 (22.5)                             9 (22.5)                                                                                         0.006                                                 0.007     
  Sulpiride                                                                                            38 (25)                                                     42 (32.6)                             8 (20.0)                                                                                         0.195                                                 0.221     
  Total (n=321)                                                                                        152 (100.0)                                                 129 (100.0)                           40 (100.0)                                                                                                                                                       
  6\. Why did you choose aripiprazole? (multiple choices)                                              Good effect                                                 88 (58.3)                             77 (60.2)                                                                                        26 (63.4)                                             0.83      0.586
  Rapid onset                                                                                          49 (32.5)                                                   40 (31.2)                             18 (43.9)                                                                                        0.307                                                 0.077     
  Few adverse effects                                                                                  103 (68.2)                                                  97 (75.8)                             32 (78.0)                                                                                        0.257                                                 0.421     
  Cheap price                                                                                          7 (4.6)                                                     4 (3.1)                               2 (4.9)                                                                                          0.784                                                 0.665     
  FDA indication                                                                                       74 (49)                                                     76 (59.4)                             28 (68.3)                                                                                        0.048                                                 0.137     
  Total (n=320)                                                                                        151 (100.0)                                                 128 (100.0)                           41 (100.0)                                                                                                                                                       
  7\. Why did you not choose aripiprazole? (multiple choices)                                          Drug effect                                                 26 (17.7)                             12 (9.4)                                                                                         2 (5)                                                 0.035     0.157
  Adverse effects                                                                                      39 (26.5)                                                   34 (26.6)                             19 (47.5)                                                                                        0.025                                                 0.042     
  Price                                                                                                64 (43.5)                                                   80 (62.5)                             20 (50.0)                                                                                        0.007                                                 0.007     
  Not knowing associated information                                                                   23 (15.6)                                                   3 (2.3)                               0 (0)                                                                                            \<0.001[b](#tfn3-ndt-11-225){ref-type="table-fn"}     \<0.001   
  Health insurance payment audit and deletion                                                          48 (32.71)                                                  39 (30.5)                             10 (25.0)                                                                                        0.646                                                 0.200     
  Total (n=315)                                                                                        147 (100.0)                                                 128 (100.0)                           40 (100.0)                                                                                                                                                       
  8\. Why did you not choose                                                                           Drug effect                                                 16 (10.8)                             17 (13.3)                                                                                        5 (12.2)                                              0.819     0.620
  Adverse effects                                                                                      44 (29.7)                                                   53 (41.4)                             14 (34.1)                                                                                        0.127                                                 0.036     
  Price                                                                                                42 (28.4)                                                   60 (46.9)                             14 (34.1)                                                                                        0.006                                                 0.022     
  Not knowing associated information                                                                   3 (2)                                                       3 (2.3)                               0 (0)                                                                                            0.623                                                 0.785     
  Health insurance payment audit and deletion                                                          79 (53.4)                                                   76 (59.4)                             13 (31.7)                                                                                        0.008                                                 \<0.001   
  Total (n=317)                                                                                        148 (100.0)                                                 128 (100.0)                           41 (100.0)                                                                                                                                                       

**Notes:**

Chi-square test

Fisher's exact test

Analysis of covariance (after including poor response proportion and remission rate as covariates). As some psychiatrists missed questions, the column totals do not equal the total number.

**Abbreviations:** ECT, electroconvulsive therapy; FDA, US Food and Drug Administration.

###### 

Multiple logistic regression analyses of the correlate variables associated with aripiprazole and quetiapine

  Models/persons                                                    Aripiprazole        Quetiapine                       
  ----------------------------------------------------------------- ------------------- ------------ ------------------- -------
  **Crude OR**                                                                                                           
  \<100                                                             1.00 (reference)    --           1.00 (reference)    --
  101--200                                                          0.95 (0.54--1.66)   0.860        2.39 (1.43--3.99)   0.001
  \>200                                                             1.63 (0.63--4.21)   0.311        0.58 (0.29--1.18)   0.133
  **Adjustment**[a](#tfn6-ndt-11-225){ref-type="table-fn"} **OR**                                                        
  \<100                                                             1.00 (reference)    --           1.00 (reference)    --
  101--200                                                          0.94 (0.50--1.77)   0.842        1.93 (1.11--3.36)   0.019
  \>200                                                             1.44 (0.52--3.99)   0.479        0.36 (0.16--0.78)   0.010

**Note:**

Adjustment for poor response proportion and remission rate.

**Abbreviations:** OR, odds ratio; CI, confidence interval.
